Transcriptomic Solution for Pet Antibody Target Discovery

Pets are facing more complex health challenges like cancer, autoimmune disorders, and ongoing inflammatory conditions. This creates a real need for new, effective treatments that can truly improve their quality of life. Creative Biolabs is leading the charge in pet therapeutic antibody discovery via transcriptomics analysis. We use cutting-edge genetic insights to find new ways to treat pet diseases, specifically by discovering novel antibody targets. We're dedicated to providing transcriptomics solution to accelerate creating the next generation of medicines for our animal companions.

Request a Consultation

Workflow of Transcriptomic based Antibody Target Discovery

Our service leverages the power of transcriptomics to identify and validate promising antibody targets for a wide range of pet diseases.

Pet Antibody Target Transcriptomics Discovery Workflow. (Creative Biolabs Original) Fig. 1 Transcriptomics Pet Antibody Target Discovery Workflow. (Creative Biolabs Original)

1. Strategic Sample Acquisition and Preparation	We work closely with our clients to develop a robust sample acquisition strategy, ensuring that tissues and cells are collected under optimal conditions to preserve the integrity of the RNA. This initial phase is critical for generating a high-fidelity snapshot of the gene expression landscape within the diseased and healthy tissues of the target pet species.
2. High-Throughput RNA Sequencing	Utilizing state-of-the-art next-generation sequencing (NGS) platforms, we perform deep RNA sequencing on the prepared samples. The depth and quality of our sequencing ensure that even rare transcripts and subtle changes in gene expression are captured with high precision.
3. Advanced Bioinformatic Analysis	Utilizing sophisticated algorithms, our expert bioinformaticians compare diseased and healthy tissues to identify differentially expressed genes. This analysis pinpoints genes that are specifically upregulated or downregulated, revealing them as potential therapeutic targets. We then perform detailed functional annotation and pathway analysis to understand their biological role in the disease's progression. This crucial step allows us to elucidate the molecular pathways involved, enabling the strategic prioritization of targets most suitable for the development of effective antibody-based therapies.
4. Rigorous Target Validation	The final and most critical step in our workflow is the validation of the identified targets. We employ a multi-pronged approach to confirm the role of the target in the disease and to assess its "druggability." This may involve in vitro assays, cell-based functional screens, and the development of proof-of-concept antibodies to evaluate the therapeutic potential of the target in relevant pet-specific models.

Why Choose Us?

Unparalleled Pet Species Expertise
Our team possesses extensive experience in applying genomic and transcriptomic technologies specifically to companion animals. This specialized knowledge enables us to design studies tailored to the unique biology of various pet species, ensuring more relevant and impactful results for your research and development needs.
Cutting-Edge Transcriptomic Technologies
We utilize the latest advancements in transcriptomic analysis, from high-throughput sequencing to sophisticated bioinformatic tools. Our investment in state-of-the-art technology ensures you receive the highest quality data with a level of precision and accuracy that is unmatched in the industry, accelerating your research with confidence.
Strategic Antibody Target Discovery
We go beyond simple gene expression to identify targets that are genuinely "druggable." Our rigorous analysis focuses on factors essential for developing effective antibody therapies, including cellular location and disease role. This strategic approach significantly increases the probability of success for your downstream drug development programs.
Actionable, Biologically-Relevant Insights
Our commitment extends beyond raw data delivery to providing clear, actionable insights grounded in biological context. We translate complex genomic information into a comprehensive understanding of disease mechanisms. This empowers your team to make informed decisions for developing next-generation diagnostics, treatments, and nutritional solutions for pets.

FAQs

1. What types of pet diseases can you help with?

Our approach is incredibly flexible and can be applied to a wide range of pet diseases, including various types of cancer, autoimmune disorders, inflammatory conditions, and infectious diseases.

2. What kind of samples do you need?

We can work with a variety of samples, including extracted RNA, fresh-frozen tissues, preserved tissues (FFPE), and isolated cells. We'll determine the specific sample requirements based on your project.

3. What kind of data and reports do you provide at the end of the project?

We provide a comprehensive data package that includes the raw sequencing data, a detailed analysis report, and a prioritized list of potential antibody targets. We also offer a post-project consultation to help you interpret the results and plan your next steps.

Related Services

In addition to our transcriptomic solutions, Creative Biolabs offers a range of other services to support your antibody discovery and development efforts:

Genomic Solution

Provides comprehensive analysis of an organism's complete set of DNA to identify genetic markers and variations associated with disease.

Proteomic Solution

A comprehensive proteomic analysis to complement our transcriptomic data and provide a more complete picture of the disease state.

In Silico Target Screening

A computational approach to screen and prioritize potential antibody targets based on their structural and functional properties.

High-Throughput Target Screening

A high-throughput screening platform to functionally validate a large number of potential antibody targets in a cost-effective and time-efficient manner.

Partner with Creative Biolabs

Creative Biolabs believes that using advanced genetic insights is transforming the way we discover antibody targets for pets. Our advanced transcriptomic platform and deep expertise in companion animals provide a powerful R&D solution for identifying and validating new antibody targets for a wide range of veterinary diseases. We're committed to helping our clients accelerate the development of next-generation veterinary medicines and ultimately, improve the health and well-being of our beloved animal companions.

Ready to advance your pet antibody discovery program? Contact us today! Our team is eager to discuss your project and help you design a customized transcriptomic solution for your veterinary monoclonal antibody discovery needs.

Contact Our Team

Services